KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

NCT05938725 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis
Lupus Nephritis - World Health Organization (WHO) Class III
Lupus Nephritis - WHO Class IV

Interventions

BIOLOGICAL: KYV-101 anti-CD19 CAR-T cell therapy
DRUG: Standard lymphodepletion regimen

Sponsor

Kyverna Therapeutics